Hudson Bay Capital Management
BBOT

Hudson Bay Capital Management’s BridgeBio Oncology BBOT Stock Holding History

Hudson Bay Capital Management’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$985K Buy
+110,000
New +$1.18M ﹤0.01% 885
2025
Q3 		– Sell
-108,300
Closed -$1.15M – 1739
2025
Q2 		$1.15M Buy
+108,300
New +$1.17M ﹤0.01% 932

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Hudson Bay Capital Management's BBOT Position: Q1 2026 in Review

Hudson Bay Capital Management opened a new position in BridgeBio Oncology (BBOT) in Q1 2026: 110,000 shares worth $985K. The stake represents ﹤0.01% of the portfolio and ranks #885 among its holdings. This is a return to the name: Hudson Bay Capital Management previously reported a position in BBOT as recently as Q2 2025.

Hudson Bay Capital Management first reported a position in BBOT in Q2 2025 and has held it in 2 quarters since. The position peaked at $1.15M in Q2 2025. 67 funds tracked by Wall St. Rank hold BBOT as of Q1 2026.

  • Hudson Bay Capital Management held 110,000 shares of BridgeBio Oncology worth $985K as of Q1 2026.
  • BridgeBio Oncology was a new Hudson Bay Capital Management position in Q1 2026.
  • BridgeBio Oncology made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #885 holding.
  • Hudson Bay Capital Management first reported a position in BridgeBio Oncology in Q2 2025 and has held it in 2 quarters since.
  • Hudson Bay Capital Management's BridgeBio Oncology position peaked at $1.15M in Q2 2025.
  • 67 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.